Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Update

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the target of a significant decline in short interest in November. As of November 15th, there was short interest totalling 21,400 shares, a decline of 42.5% from the October 31st total of 37,200 shares. Based on an average daily volume of 77,100 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.3% of the company’s stock are sold short.

Sol-Gel Technologies Price Performance

Shares of SLGL remained flat at $0.58 during mid-day trading on Thursday. 24,153 shares of the stock were exchanged, compared to its average volume of 138,544. The company has a market cap of $16.02 million, a P/E ratio of -1.69 and a beta of 1.60. The business’s fifty day moving average price is $0.61 and its 200 day moving average price is $0.67. Sol-Gel Technologies has a one year low of $0.33 and a one year high of $1.58.

Wall Street Analyst Weigh In

Separately, Raymond James cut Sol-Gel Technologies from a “strong-buy” rating to an “outperform” rating and reduced their price target for the stock from $6.00 to $4.00 in a report on Monday, August 19th.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.